Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis

Patients with eosinophilic gastritis, duodenitis, or both conditions were randomly assigned to receive placebo or AK002, an anti–Siglec-8 antibody that depletes eosinophils and inhibits mast cells. AK002 reduced eosinophils and symptoms, with frequencies of adverse events similar to placebo, althoug...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-10, Vol.383 (17), p.1624-1634
Hauptverfasser:	Dellon, Evan S, Peterson, Kathryn A, Murray, Joseph A, Falk, Gary W, Gonsalves, Nirmala, Chehade, Mirna, Genta, Robert M, Leung, John, Khoury, Paneez, Klion, Amy D, Hazan, Sabine, Vaezi, Michael, Bledsoe, Adam C, Durrani, Sandy R, Wang, Chao, Shaw, Camilla, Chang, Alan T, Singh, Bhupinder, Kamboj, Amol P, Rasmussen, Henrik S, Rothenberg, Marc E, Hirano, Ikuo
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdomen Adolescent Adult Aged Animal models Antibodies Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacology Antigens, CD - immunology Antigens, Differentiation, B-Lymphocyte - immunology Biopsy Diarrhea Dose-Response Relationship, Drug Double-Blind Method Duodenitis Duodenitis - complications Duodenitis - drug therapy Enteritis - complications Enteritis - drug therapy Eosinophilia Eosinophilia - complications Eosinophilia - drug therapy Eosinophils Esophagus FDA approval Female Gastritis Gastritis - complications Gastritis - drug therapy Gastrointestinal diseases Gastrointestinal Tract - immunology Humans Infusions, Intravenous - adverse effects Lectins - antagonists & inhibitors Lectins - immunology Leukocyte Count Leukocytes (eosinophilic) Male Mast cells Middle Aged Mucosa Nausea Pain Patients Population Quality of life Questionnaires Statistical analysis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with eosinophilic gastritis, duodenitis, or both conditions were randomly assigned to receive placebo or AK002, an anti–Siglec-8 antibody that depletes eosinophils and inhibits mast cells. AK002 reduced eosinophils and symptoms, with frequencies of adverse events similar to placebo, although infusion-related reactions were more common with AK002.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2012047